Related Experiment Videos
[Voluntary lithium salt poisoning; risks of slow release forms]
B Branger1, H Peyrière, B Zabadani
1Service de médecine C et de néphrologie, CHU, Nîmes.
Nephrologie
|December 16, 2000
Summary
Sustained-release lithium carbonate, while stabilizing drug levels, poses a higher overdose risk. Two hemodialysis sessions are recommended for severe intoxication due to potential lithium rebound and neurological complications.
Area of Science:
- Pharmacology
- Nephrology
- Toxicology
Background:
- Lithium carbonate is a key treatment for bipolar disorder (manic-depressive illness).
- Slow-release formulations improve drug stability and allow once-daily dosing.
- However, sustained-release forms increase the risk of severe lithium overdose due to continuous drug release.
Observation:
- Three cases of life-threatening overdose with sustained-release lithium salts are presented.
- Hemodialysis was required to manage elevated plasma lithium levels.
- Lithium rebound and severe neurological disorders occurred in two patients after initial hemodialysis.
Findings:
- Severe intoxication with sustained-release lithium carbonate necessitates careful management.
- Lithium levels can rebound after a single hemodialysis session.
- Rebound intoxication is associated with significant neurological complications.
Implications:
- This study highlights the critical need for at least two hemodialysis sessions in severe slow-release lithium carbonate intoxication.
- Clinicians should be vigilant for lithium rebound and neurological sequelae.
- Treatment protocols for lithium overdose may require revision for sustained-release formulations.